Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride implant
- Development stage
- Approved
- Lead developer
- Innocoll
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Surgical Implant
01
Overview
XaraColl is a non-injectable drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride. It is designed to provide postsurgical pain relief for up to 24 hours following open inguinal hernia repair in adults. Each XaraColl collagen implant (5 cm × 5 cm × 0.5 cm) contains 100 mg bupivacaine HCl (equivalent to 88.8 mg bupivacaine) and 75 mg purified Type I collagen. The recommended dose is 300 mg (3 x 100 mg implants). XaraColl works by releasing bupivacaine immediately and over time through diffusion from the porous collagen implant, which dissolves over time. Bupivacaine blocks the generation and conduction of nerve impulses, providing local anesthesia.
- Brand names
- Xaracoll
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)PTGER1 (Prostaglandin E Receptor 1)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bupivacaine hydrochloride implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride implant.